Navigation Links
Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002
Date:5/2/2011

PLYMOUTH, Mich., May 2, 2011 /PRNewswire/ -- Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the results from a Phase 1 study and four preclinical studies for ETC-1002 at the Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions in Chicago.  In the Phase 1 study, treatment with ETC-1002 was shown to be safe and well tolerated and to significantly reduce LDL-C levels in subjects with mild dyslipidemia.

ETC-1002, the company's lead product candidate, is a novel small molecule that has demonstrated preclinical and clinical activity as a metabolic regulator of imbalances in lipid and carbohydrate metabolism.  It is being developed to treat dyslipidemia and other cardio-metabolic risk factors.  Mechanistic studies indicate that treatment with ETC-1002 increases AMP-kinase phosphorylation, inhibits fatty acid and cholesterol synthesis and also enhances fatty acid oxidation.   In the Phase 1 study, treatment with ETC-1002 resulted in consistent, dose-related reductions in LDL-C.  The randomized, double-blind, placebo-controlled study included 32 subjects treated with daily doses of ETC-1002 up to 120 mg or placebo for 14 days and 21 subjects treated with 120 mg of ETC-1002 or placebo for 28 days.

"Cardio-metabolic diseases remain the number one cause of death in people around the world, and research indicates that an effective agent to manage both plasma lipids and glucose could offer significant benefit to millions of patients.  The results of our Phase 1 study show a statistically significant lowering of LDL-C in mildly dyslipidemic subjects and a favorable safety profile, and serve as a solid foundation for clinical evaluation in patients with other cardio-metabolic abnormalities," said Roger Newton, PhD, President and CEO of Esperion.

In addition to the result
'/>"/>

SOURCE Esperion Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
2. TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
3. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
5. Samplify Systems Announces Availability of Prism FP Floating Point Compression
6. Vertical Health Solutions to Begin Doing Business as OnPoint Medical Diagnostics and Announces Completion of Symbol Change
7. ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011
8. BioMarin Announces First Quarter 2011 Financial Results
9. IRIDEX Announces First Quarter 2011 Conference Call and Release Date
10. Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 13th International Myeloma Workshop
11. OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... According to a new market ... Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), Lab Devices ... WPW) - Global Forecasts to 2019 ", published by MarketsandMarkets, ... ~$4.73 Billion by 2019 with a CAGR of around ... Browse   90   ma rket ...
(Date:3/27/2015)... , March 27, 2015 As ... shipments of incontinence devices for women. ... the most gratifying part is the hundreds of ... women whose lives have been positively impacted by ... of InControl. InControl recently released Apex, ...
(Date:3/27/2015)... The International Myeloma Foundation (IMF) – improving ... toward prevention and a cure – today commended Representative ... resolution (H. Res. 174) that supports the designation of ... Awareness Month." Currently there are more than ... 110,000 new cases are diagnosed yearly, according to the ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... May 5 OrthoAccel Technologies, Inc. announced that it has entered ... to introduce the AcceleDent System to the Australian market. , ... (Logo: http://www.newscom.com/cgi-bin/prnh/20091029/DA01250LOGO ) , ... AcceleDent, an acceleration device to enhance orthodontics, was introduced ...
... Instrumentation Laboratory (IL) today announced total worldwide sales in 2009 ... growth v. previous year in current, and 13.2% in local currencies.  In ... growth in local currencies was 13.2% and 12.4%, respectively. , ... "In spite of the major economic downturn, ...
Cached Medicine Technology:OrthoAccel Technologies, Inc. and AB Orthodontics Announce Partnership and Australian Product Introduction 2OrthoAccel Technologies, Inc. and AB Orthodontics Announce Partnership and Australian Product Introduction 3OrthoAccel Technologies, Inc. and AB Orthodontics Announce Partnership and Australian Product Introduction 4Instrumentation Laboratory Achieves Record Sales in 2009 2Instrumentation Laboratory Achieves Record Sales in 2009 3
(Date:3/27/2015)... Omaha, NE (PRWEB) March 27, 2015 Ticket ... tickets at the CenturyLink Center in Omaha, Nebraska on ... a possibility that more concert dates will be added in ... result of fan demand. , The Garth Brooks World Tour ... with the latest announcement that Garth Brooks and Trisha Yearwood ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 According to ... http://www.idataresearch.com ), the plate and screw market in Europe ... the generic plate and screw segment. Price decreases are ... Despite representing almost 50% of the total European trauma ... decrease the total market value, year after year. ...
(Date:3/27/2015)... LONDON, UK (PRWEB) March 27, 2015 ... SiteStart Melissa (Liss) Easy was named to the 2015 ... 40 Under 40 list spotlights 40 dynamic, up-and-coming leaders ... accomplishments and community involvement. Winners are honored at an ... supplement of the Philadelphia Business Journal. , Lyn Kremer, ...
(Date:3/27/2015)... On March 19, 2015, at Detroit’s ... wide receiver Herman Moore, hosted “Fighting Addiction Together,” ... abuse, treatment options and the recent changes in ... ministers and bishops from local churches as well ... “Our ‘Fighting Addiction Together’ luncheon was informative and ...
(Date:3/27/2015)... CA (PRWEB) March 27, 2015 Endure ... Yoga for functional fitness athletes. This new program matches ... specific protocol for post-workout cool down. This program utilizes ... breath control and mental focus. , Karen Lefurgy, ... started practicing yoga long before I started Crossfit® training, ...
Breaking Medicine News(10 mins):Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 2Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 3Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:LiveToBeSober.org Hosts Conference on Substance Abuse Treatment and Recovery at Ford Field 2Health News:Endure Yoga Introduces WOD Recovery Yoga 2
... In medical breakthrough research findings, researchers have been able ... which had significant brain degeneration. ,Researchers from University ... so that the mice have a clinical condition very ... researchers used transgene to check the loss of memory. ...
... form of the enzyme aldehyde dehydrogenase// (ALDH)that is responsible ... consuming alcohol. ,Researchers from Mitsukoshi Health and Welfare ... to hangovers in individuals who have a particular genetic ... important enzyme involved in the removal of acetaldehyde, which ...
... women with sexual difficulties was rejected by a panel of ... ,Procter & Gamble, global manufacturer of household products, ... menopausal after ovarian surgery however due to the rejection by ... hold until more data is available to assess the drug. ...
... a “black box warning” to three asthma drugs//, ... advised the manufacturers that the drug should carry ... breathing. ,Adavir and Serevent are manufactured ... manufacturers the drug Foradil which contains a different ...
... constantly coming up with new strategies// and technologies to ... ,Deputy director BK Karna of Indian Institute ... bring in novel features to prevent proliferation of duplicated ... closure and tamper evidence packaging they are yet to ...
... University of California-San Francisco has published that weight loss// ... by increasing heart beat rate and blood pressure. ... homeostasis. ,The study spearheaded by Dr. Christine A. ... experimental group of 16 healthy adults. Two tests were ...
Cached Medicine News:Health News:Testosterone patch for women Rejected For safety Reasons 2Health News:FDA gives “black box warning” against three asthma dru 2Health News:The Use of Radio Frequency Identification ( RFID) to tackle the growing menace of counterfeit drugs 2
... OraQuick is an FDA ... venipuncture whole blood test used ... of HIV-1 infection. This CLIA ... presence of antibodies to HIV-1, ...
... QuickVue+ Infectious Mononucleosis test is ... antibodies in serum, plasma or whole ... utilizes an extract of bovine erythrocytes ... specificity than similar extracts prepared from ...
... the first available point-of-care diagnostic test that ... of influenza A and B. The test ... an enzyme that assists viral replication by ... infected cells. The ZstatFlu substrate is labeled ...
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
Medicine Products: